

# Interaction effects of diabetes and brain-derived neurotrophic factor on suicidal ideation in patients with acute coronary syndrome

**Wonsuk Choi**

Chonnam National University Medical School

**Ju-Wan Kim**

Chonnam National University Medical School

**Hee-Ju Kang**

Chonnam National University Medical School

**Hee Kyung Kim**

Chonnam National University Medical School

**Ho-Cheol Kang**

Chonnam National University Medical School

**Ju-Yeon Lee**

Chonnam National University Medical School

**Sung-Wan Kim**

Chonnam National University Medical School

**Young Joon Hong**

Chonnam National University Medical School

**Youngkeun Ahn**

Chonnam National University Medical School

**Myung Ho Jeong**

Chonnam National University Medical School

**Robert Stewart**

King's College London

**Jae-Min Kim** (✉ [jmkim@chonnam.ac.kr](mailto:jmkim@chonnam.ac.kr))

Chonnam National University Medical School

---

## Original investigation

**Keywords:** suicidal ideation, acute coronary syndrome, BDNF, diabetes, interaction

**Posted Date:** March 30th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-326048/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

# Abstract

## Background

Acute coronary syndrome (ACS) is associated with an increased risk of suicide. Although both diabetes and the brain-derived neurotrophic factor (BDNF) pathway are closely related to ACS and suicide, the effects of these factors on suicidal behavior in ACS patients have not been assessed. The aim of this study was to investigate the individual and interaction effects of diabetes and BDNF-related markers, namely the serum BDNF (sBDNF) level and the *BDNF* Val66Met polymorphism, on suicidal ideation (SI) in ACS patients.

## Methods

The presence of diabetes was ascertained, and sBDNF levels and the presence of the *BDNF* Val66Met polymorphism were measured in 969 patients within 2 weeks after an ACS episode. Among these patients, 711 were followed up at 1 year after the ACS episode. SI was evaluated using the relevant items of the Montgomery–Åsberg Depression Rating Scale at baseline (acute SI) and the 1-year follow-up (chronic SI).

## Results

Significant individual effects of low sBDNF levels were found on acute SI. The presence of both diabetes and a low sBDNF level or the *BDNF* Met/Met genotype was associated with acute SI, with multivariate logistic regression analyses revealing significant interaction effects. The highest frequency of chronic SI was seen in diabetic patients with an sBDNF level in the lowest tertile or with the *BDNF* Met/Met genotype, although the interaction terms were not statistically significant.

## Conclusions

Combining diabetes and BDNF-related markers, such as the sBDNF level and the *BDNF* Val66Met polymorphism, might provide a useful predictor of acute SI in patients with ACS.

## 1. Background

Suicide is a global public health problem and is responsible for approximately 1 million deaths each year [1]. Acute coronary syndrome (ACS), which comprises unstable angina and myocardial infarction, is a serious life stressor that results in a high risk of suicidal behavior [2–5]. Moreover, suicidal ideation (SI) after ACS may be a risk factor for adverse cardiac outcomes [6]. Given the relationship between ACS and suicide and the burdens of both, identifying risk factors for ACS-related suicidal behavior is important for developing effective prevention strategies for these patients.

Diabetes is a highly prevalent comorbidity among ACS patients and is associated with early mortality and major adverse cardiovascular events [7–9]. Diabetes also increases the risk of suicide [10, 11]. However, whether diabetes is an additional risk factor for suicide in ACS patients has not been determined.

Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, may contribute to suicide risk after ACS given its associations with both suicide and ACS. The involvement of BDNF in atherogenesis and plaque instability [12] was supported by a clinical study that reported reduced levels of BDNF in ACS patients [13]. BDNF has also been implicated in suicidal behavior based on its role in maintaining synaptic and structural plasticity in the central nervous

system [14, 15]. However, inconsistent results regarding the association between the serum BDNF (sBDNF) level and suicidal behavior have been reported in previous studies. Some studies have reported that a high sBDNF level is associated with a higher suicide risk [16–18], whereas others found no such significant association [19, 20]. Because the expression of *BDNF* is influenced by a genetic polymorphism entailing substitution of valine by methionine at codon 66 (Val66Met) in the pro-BDNF molecule, which is associated with reduced activity-dependent secretion of BDNF [21], clinical studies have been conducted to evaluate the association between *BDNF* Val66Met polymorphism and suicide risk. However, inconsistent results have been reported. Some studies have reported that the *BDNF* Met/Met genotype is associated with higher suicide risk [22–24], whereas others have found no significant association [25, 26].

Because diabetes and the BDNF pathway are closely related to ACS and suicide, respectively, and the level and function of BDNF are disrupted in diabetes [27, 28], suicidal behavior in ACS patients may be influenced by a potentially complex association between diabetes and the BDNF pathway. On the spectrum of suicidal behaviors, which range from SI and suicide attempts to completion [29], SI has been used as a phenotype of suicidal behavior in ACS patients in previous studies [30, 31]. Using data from a prospective study of Korean patients with ACS, we investigated the interaction effects of diabetes and BDNF-related markers, i.e., the sBDNF level and *BDNF* Val66Met polymorphism, on acute (within 2 weeks after an ACS episode) and chronic (1 year after an ACS episode) SI in patients with ACS.

## 2. Methods

### 2.1 Study outline and participants

All analyses were carried out using data from the DEPRESSION in ACS (DEPACS) study, which design and main findings have been published [32–34]. The outline and participant recruitment process for the present analysis are presented in **Supplementary Fig. 1**. Participants were consecutively recruited from patients recently hospitalized with ACS at the Department of Cardiology of Chonnam National University Hospital, Gwangju, South Korea from 2006 to 2012. This Department was nominated by the Korean Circulation Society to serve as the central coordinating center for the Korea Acute Myocardial Infarction Registry [35]. The study cardiologists treated patients according to international guidelines for the management of ACS [36]. Patients who satisfied the inclusion criteria and consented to take part in the study were examined for baseline evaluations as inpatients within 2 weeks (mean 6.3 standard deviation 2.4 days) post-ACS. Within this group, those who agreed to blood collections comprised the baseline sample. They were approached at 1-year after ACS for follow-up evaluation.

This study was approved by the Chonnam National University Hospital Institutional Review Board (CNUH I-2008-02-027).

All participants reviewed the consent form and written informed consent was obtained.

### 2.2 Eligibility criteria for the DEPACS participants

For the DEPACS study entry, inclusion criteria were as follows: i) aged 18 ~ 85 years; ii) confirmed ACS by investigation (the presence of ST-segment elevation MI was determined by > 30 min of continuous chest pain, a new ST-segment elevation  $\geq 2$  mm on at least two contiguous electrocardiographic leads, and creatine kinase-MB more than three times normal; the presence of non-ST-segment elevation MI was diagnosed by chest pain and a positive cardiac biochemical marker without new ST-segment elevation; and the presence of unstable angina was determined by chest pain within the preceding 72 h with or without ST-T wave changes or positive cardiac biochemical markers); iii) ability to complete study questionnaires; iv) ability to understand the study objectives and sign informed consent. Exclusion criteria were: i) occurrence of ACS while hospitalized for another reason; ii) ACS developing less than 3 months after a coronary artery bypass graft procedure; iii) uncontrolled hypertension (systolic blood pressure (BP) > 180mmHg or diastolic BP > 100mmHg), the same criteria were used in the SADHART trial [37]; iv) resting heart rate < 40/min; v) severe physical

illnesses threatening life or interfering with the recovery from ACS; vi) persistent clinically significant laboratory abnormalities in complete blood cell counts, thyroid tests, renal function tests, and liver function tests

## 2.3 Exposure variables

### 2.3.1 Assessment of diabetes

Information regarding history of diabetes was obtained at the baseline evaluation. Presence of diabetes was defined as a diagnosis of diabetes by a doctor or currently receiving oral hypoglycemic agents or insulin treatment.

### 2.3.2 Serum BDNF level

Participants were instructed to fast (except water) overnight prior to blood sampling.

Participants were then asked to sit quietly and relax for 25–45 min before obtaining the blood samples.

The sBDNF level was measured using the Quantikine® ELISA Human BDNF Immunoassay (R&D Systems, Inc., Minneapolis, MN, USA) at the Global Clinical Central Lab (Yongin, Korea). The sBDNF level was classified into tertiles (high, middle, or low). Additionally, the patients were divided according to the median sBDNF level into higher and lower groups.

### 2.3.3 *BDNF* genotyping

The *BDNF* Val66Met polymorphism was identified as follows: DNA was extracted from venous blood using standard procedures. Polymerase chain reaction (PCR) and PCR-based restriction fragment length polymorphism assays were conducted. The forward and reverse primers had the sequences 5'-ACTCTGGAGAGCGTGAATGG-3' and 5'-ACTACTGAGCATCACCTGGA-3', respectively. The amplification conditions were pre-denaturation at 95°C for 5 min followed by 40 cycles of denaturation at 95°C for 30 s, 62°C for 30 s, and 72°C for 30 s, with post-elongation at 72°C for 5 min and a final maintenance step at 4°C. The PCR products were digested at 37°C with the corresponding restriction enzyme (*Eco72I*) and separated by gel electrophoresis to identify the 196G (Val: 99- and 72-bp fragments) and 196A (Met: 171-bp fragment) alleles. The genotype was categorized as Val/Val, Val/Met, or Met/Met.

## 2.4 Baseline covariates

Data on the covariates strongly associated with suicide in ACS patients in previous reports [38] were evaluated within 2 weeks after ACS. An assessment was performed to collect information on age, sex, years of education, living status (living alone or not), type of residence (owned or rented), and current occupation (employed or not). To assess patients' depression characteristics, personal and family histories of depression and Beck Depression Inventory (BDI) [39] were evaluated. To assess patients' cardiovascular risk factors, the following characteristics were also investigated: personal and family histories of ACS, diagnosed hypertension, hypercholesterolemia according to fasting serum total cholesterol level (> 200 mg/dL) or a history of hyperlipidemia with ongoing treatment, obesity based on measured body mass index (BMI, > 25 kg/m<sup>2</sup>), and reported current smoking status. To estimate current cardiac status, ACS severity was evaluated using the Killip classification [40], left ventricular ejection fraction (LVEF) was measured using echocardiography. Serum cardiac biomarkers, including troponin I and creatine kinase (CK)-MB, were also assessed.

## 2.5 Outcome measure: Suicidal ideation

SI was assessed within 2 weeks after ACS (acute SI) and at 1-year after ACS (chronic SI) using the items on the Montgomery–Åsberg Depression Rating Scale (MADRS) addressing suicidal thoughts [41]. Respondents were asked to rate whether they thought life was worth living or whether they had a suicide plan; scores ranged from 0 (life satisfaction) to 6 (explicit plans for suicide). Following previous studies, the presence of SI was defined by a score of 2 (fleeting suicidal thoughts) or more [42].

## 2.6 Statistical analysis

The baseline data of diabetes presence, sBDNF tertiles, presence of the *BDNF* val66met polymorphism, and presence of acute SI were compared using independent *t*-tests or chi-square tests. Covariates for the later adjusted analyses were chosen based on variables that exhibited statistical significance ( $P < 0.05$ ) in these analyses and potential collinearity among variables. The individual effects of diabetes (absent vs. present), the sBDNF level (high vs. middle or low), and the *BDNF* Val66Met polymorphism (Val/Val vs. Val/Met or Met/Met) on acute and chronic SI were analyzed using logistic regression before and after adjusting for potential covariates. The interaction effects between diabetes and the sBDNF level or *BDNF* Val66Met polymorphism and between the sBDNF level and *BDNF* Val66Met polymorphism on acute and chronic SI were analyzed by multinomial logistic regression after adjusting for potential covariates. All statistical tests were two-sided, and a  $P$ -value  $< 0.05$  was considered to indicate statistical significance. Statistical analyses were performed using IBM SPSS Statistics (version 25).

## 3. Results

### 3.1 Recruitment and treatment

Patient recruitment over the 1-year period is shown in **Supplementary Fig. 1**. Among the 1,152 patients evaluated at baseline, 969 (84.1%) consented to offer blood samples. The baseline covariates did not differ significantly between those who agreed to blood collection and those who refused. Re-evaluation at 1 year after the ACS episode was performed in 711 (73.4%) of the 969 patients. Reasons for drop-out were loss to follow-up ( $N = 159$ ), death ( $N = 9$ ), refusal to participate ( $N = 32$ ), and too unwell to participate ( $N = 13$ ). Drop-out at the 1-year re-evaluation was significantly associated with older age and higher Killip class but not with diabetes, the sBDNF level, or presence of the *BDNF* Val66Met polymorphism.

### 3.2 Baseline characteristics of presence of diabetes, sBDNF tertiles, presence of the *BDNF* Val66Met polymorphism, and acute SI

In the baseline sample ( $N = 969$ ), diabetes was present in 191 (19.7%) participants. The median (interquartile range) and mean (standard deviation) sBDNF levels were 17.8 (7.0) and 17.6 (9.4) ng/mL, respectively. The sBDNF levels were divided into tertiles: high (20.50–52.61 ng/mL), middle (14.79–20.48 ng/mL), and low (1.37–14.79 ng/mL). Val/Val, Val/Met, and Met/Met genotypes were present in 242 (25.0%), 498 (51.4%), and 229 participants (23.6%), respectively. Acute SI was present in 195 (20.1%) participants. These variables were compared according to diabetes presence in Table 1. Presence of diabetes was significantly associated with older age, female sex, lower education level, current unemployment, higher score on the BDI, hypertension, hypercholesterolemia, lower rate of current smoking, and lower LVEF. The characteristics were compared according to the sBDNF tertile and presence of the *BDNF* Val66Met polymorphism in **Supplementary Table 1** and **Supplementary Table 2**, respectively. The sBDNF tertile was significantly associated with current unemployment, hypertension, current smoking, and LVEF. Presence of *BDNF* Val66Met polymorphism was significantly associated with the sBDNF level, age, current unemployment, and BDI score. The characteristics were then compared according to presence of acute SI in **Supplementary Table 3**. The presence of acute SI was significantly associated with female sex, lower education level, rented housing, current unemployment, previous depression, and a higher score on the BDI. Based on variables that exhibited statistical significance ( $P < 0.05$ ) in these analyses and potential collinearity among the variables, eleven variables (age, sex, education, housing, currently unemployed, previous depression, BDI score, hypertension, hypercholesterolemia, current smoker, and LVEF) were selected for evaluation in the subsequent adjusted analyses.

Table 1

Comparisons of baseline characteristics according to diabetes presence in patients with acute coronary syndrome

	Non-diabetics (N = 778)	Diabetics (N = 191)	Statistical coefficient <sup>a</sup>	P-value
<b>Socio-demographic characteristics</b>				
Age, mean (SD) years	57.1 (11.2)	62.4 (9.6)	t = -6.526	P < 0.001
Sex, N (%) female	199 (25.6)	70 (36.6)	$\chi^2 = 9.372$	P = 0.002
Education, mean (SD) years	10.0 (4.6)	9.2 (4.7)	t = 2.029	P = 0.043
Marital status, N (%) unmarried	113 (14.5)	28 (14.7)	$\chi^2 = 0.002$	P = 0.962
Living alone, N (%)	70 (9.0)	22 (11.5)	$\chi^2 = 1.134$	P = 0.287
Housing, N (%) rented	129 (16.6)	21 (11.0)	$\chi^2 = 3.658$	P = 0.056
Currently unemployed, N (%)	277 (35.6)	91 (47.6)	$\chi^2 = 9.438$	P = 0.002
<b>Depression characteristics</b>				
Previous depression, N (%)	25 (3.2)	9 (4.7)	$\chi^2 = 1.107$	P = 0.313
Family history of depression, N (%)	18 (2.3)	5 (2.6)	$\chi^2 = 0.061$	P = 0.805
BDI, mean (SD) score	9.6 (8.5)	11.5 (9.0)	t = -2.746	P = 0.006
<b>Cardiac risk factors, N (%)</b>				
Previous ACS	31 (4.0)	8 (4.2)	$\chi^2 = 0.017$	P = 0.898
Family history of ACS	24 (3.1)	7 (3.7)	$\chi^2 = 0.167$	P = 0.683
Hypertension	338 (43.4)	120 (62.8)	$\chi^2 = 23.114$	P < 0.001
Hypercholesterolemia	403 (51.8)	83 (43.5)	$\chi^2 = 4.271$	P = 0.039
Obesity	336 (43.2)	79 (41.4)	$\chi^2 = 0.209$	P = 0.648
Current smoker	319 (41.0)	47 (24.6)	$\chi^2 = 17.538$	P < 0.001
<b>Current cardiac status</b>				

<sup>a</sup>Independent two-sample t-test or  $\chi^2$  test, as appropriate. BDI, Beck Depression Inventory; ACS, acute coronary syndrome; LVEF, left ventricular ejection fraction; CK-MB, creatine kinase-MB

	Non-diabetics (N = 778)	Diabetics (N = 191)	Statistical coefficient <sup>a</sup>	P-value
Killip class > 1, N (%)	129 (16.6)	39 (23.2)	$\chi^2 = 1.576$	P = 0.209
LVEF, mean (SD)	61.8 (10.8)	58.6 (12.7)	t = 3.237	P = 0.001
Troponin I, mean (SD) mg/dL	9.9 (15.1)	10.0 (14.2)	t = -0.127	P = 0.899
CK-MB, mean (SD) mg/dL	17.6 (37.8)	16.4 (35.1)	t = 0.413	P = 0.680
<sup>a</sup> Independent two-sample t-test or $\chi^2$ test, as appropriate. BDI, Beck Depression Inventory; ACS, acute coronary syndrome; LVEF, left ventricular ejection fraction; CK-MB, creatine kinase-MB				

### 3.3 Effects of diabetes, sBDNF tertile, and *BDNF* Val66Met polymorphism on SI

The individual effects of diabetes, sBDNF tertile, and *BDNF* Val66Met polymorphism on SI are shown in Table 2. Diabetes was not significantly associated with SI. Compared with the high sBDNF tertile, the low tertile was significantly associated with acute SI in the adjusted analyses. Compared with the Val/Val genotype, the Val/Met and Met/Met genotypes were significantly associated with acute SI in the unadjusted analyses, but these associations were not significant after adjustment. In the 1-year follow-up evaluation (N = 711), presence of diabetes, sBDNF tertile, and presence of *BDNF* Val66Met polymorphism were not significantly associated with chronic SI in the unadjusted or adjusted analyses.

Table 2

Individual effects of diabetes, BDNF Val66Met polymorphism, and tertiles of serum BDNF levels on acute and chronic suicidal ideation in patients with acute coronary syndrome.

Exposure	Group	Acute suicidal ideation				Chronic suicidal ideation			
		N	No. (%) presence	OR (95% CI)		N	No. (%) presence	OR (95% CI)	
				Unadjusted	Adjusted <sup>a</sup>			Unadjusted	Adjusted <sup>a</sup>
Diabetes	Absent	778	148 (19.0)	1.00	1.00	569	63 (11.1)	1.00	1.00
	Present	191	47 (24.6)	1.39 (0.96–2.02)	1.11 (0.69–1.80)	142	24 (16.9)	1.63 (0.98–2.72)	1.50 (0.86–2.62)
sBDNF	High	323	60 (18.6)	1.00	1.00	228	26 (11.4)	1.00	1.00
	Middle	323	59 (18.3)	0.98 (0.66–1.46)	1.05 (0.65–1.70)	249	34 (13.7)	1.21 (0.71–2.08)	1.37 (0.77–2.42)
	Low	323	76 (23.5)	1.35 (0.92–1.97)	1.73 (1.08–2.79)*	234	27 (11.5)	0.99 (0.56–1.75)	1.04 (0.57–1.91)
BDNF genotype	Val/Val	242	36 (14.9)	1.00	1.00	173	18 (10.4)	1.00	1.00
	Val/Met	498	106 (21.3)	1.55 (1.02–2.34)*	1.36 (0.83–2.25)	378	47 (12.4)	1.22 (0.69–2.18)	1.07 (0.58–1.96)
	Met/Met	229	53 (23.1)	1.72 (1.08–2.75)*	1.40 (0.80–2.47)	160	22 (13.8)	1.37 (0.71–2.67)	1.25 (0.63–2.51)
<sup>a</sup> Adjusted for age, sex, education, housing, current unemployment, previous depression, BDI score, hypertension, hypercholesterolemia, current smoking, and LVEF. BDNF, brain-derived neurotrophic factor. *P < 0.05.									
<b>Supplementary Fig. 1.</b> Participant recruitment and treatment									

The interaction effects of diabetes and sBDNF tertile on acute and chronic SI are shown in Fig. 1. Diabetes was significantly associated with both acute and chronic SI only among those in the low sBDNF tertile, and significant interactions with acute SI but not with chronic SI were found after adjustment for relevant covariates. The interaction effects of diabetes and *BDNF* Val66Met polymorphism on acute and chronic SI are shown in Fig. 2. Diabetes was significantly associated with both acute and chronic SI only in the presence of the *BDNF* Met/Met genotype, and a significant interaction with acute SI but not with chronic SI was found after adjustment for the relevant covariates. The interaction effects of the sBDNF level and *BDNF* Val66Met polymorphism on acute and chronic SI are shown in **Supplementary Fig. 2**. No significant effects were found.

## 4. Discussion

In the present study, using data from a prospective study of Korean patients with ACS, we identified significant interaction effects of diabetes with both the sBDNF level and *BDNF* Val66Met polymorphism on acute SI, in that the incidence of acute SI was significantly higher in the presence of diabetes and a low sBDNF level or the *BDNF* Met/Met



genotype compared with higher *BDNF* levels and other genotypes. These findings were robust after adjustment for relevant covariates. Although the frequency of chronic SI was higher among diabetic patients with an sBDNF level in the lowest tertile or with the *BDNF* Met/Met genotype, the interactions were not statistically significant. With respect to individual effects, a significant association was found only between a lower sBDNF level and the presence of acute SI.

Diabetes reportedly increases the risk of suicide [10, 11], presumably due to diabetes-related complications and the high prevalence of mental disorders such as depression and anxiety [43–45]. These associations depend on the type of diabetes. Juvenile type 1 diabetes is closely related to all suicidal behaviors [46–48], whereas in adult diabetics, the majority of whom have type 2 diabetes, inconsistent results have been reported regarding an increased risk of suicidal behavior. One study reported that diabetes was a risk factor for suicide completion [49], whereas others reported no relationship [50–52]. The average and median age of diabetic patients included in this study were 62.4 years (standard deviation 9.6 years) and 64.0 years (interquartile range 14.0 years), respectively, and it is considered that most of them has type 2 diabetes. Our finding that diabetes exhibited no independent effect on acute or chronic SI was consistent with the results of many previous studies.

Because BDNF is involved in synaptic and structural plasticity in the brain [14, 15], abnormal BDNF function has been suggested as a biological pathway for suicide. Based on this suggestion, many clinical studies have evaluated the association between the BDNF pathway, including the sBDNF level and *BDNF* Val66Met polymorphism, and suicidal behavior, but the results have been inconsistent. Regarding the sBDNF level, some studies have reported an association between low sBDNF levels and a higher risk of suicidal behavior [16–18], whereas others have reported no such association [19, 20]. Regarding the *BDNF* Val66Met polymorphism, some studies have found an association between the *BDNF* Met/Met genotype and a higher risk of suicidal behavior [22–24], whereas others have not [25, 26]. The discrepant findings among previous studies may be the result of differences in the assessment methods for suicidal behavior and the presence and type of underlying mental disorders in the study subjects. However, inconsistent results were also found between two studies with similar study designs that evaluated the association between *BDNF* Val66Met polymorphism and suicide attempts in patients with depressive disorders [24, 25]. In the present study, high versus low tertiles of sBDNF levels showed an independent effect on acute SI, but the *BDNF* genotype did not, thus revealing discrepant results between the two BDNF-related markers. Considering our and others' results comprehensively, BDNF-related markers alone seem to have limited value in predicting suicide risk.

In the present study, we identified an interaction effect of diabetes and a low sBDNF level or the *BDNF* Met/Met genotype on acute SI. In addition, although there were no significant interaction effects, the frequency of chronic SI was higher in diabetic patients with an sBDNF level in the lowest tertile or with the *BDNF* Met/Met genotype. A synergistic effect between diabetes and a low sBDNF level or the *BDNF* Met/Met genotype in our cohort is biologically plausible. A low peripheral BDNF level is associated with diabetes-related complications [53, 54]. Because diabetes-related complications are related to a higher risk of SI [43], diabetes may be predictive of SI only in subjects with low sBDNF levels or with the *BDNF* Met/Met genotype due to the high burden of those complications. In addition, because psychiatric diseases such as depression and anxiety are associated with increased suicidality in diabetics [43–45], and a low sBDNF level and the *BDNF* Met/Met genotype are closely related to these psychiatric diseases [55], diabetes may be a risk factor for SI only among subjects with a low sBDNF level or with the *BDNF* Met/Met genotype because of their high vulnerability to psychiatric diseases.

It is noteworthy that interaction effects between diabetes and a low sBDNF level or the *BDNF* Met/Met genotype on SI were significant during the first 2 weeks but not at 1 year after an ACS episode. These results suggest that SI in ACS patients has several possible etiologies, which may vary depending on the time elapsed since the ACS diagnosis. Recently diagnosed ACS is associated with severe emotional and physical distress [56, 57], and the interaction effects of

diabetes and altered BDNF-related markers may amplify these precipitating causes of acute SI. However, in the chronic phase, these interaction effects may disappear due to the greater influence of other factors on SI.

Several limitations to this study should be borne in mind in the interpretation of our results. First, SI, rather than suicide attempts or suicide completion, was investigated as the primary outcome. Although SI is closely related to more severe suicidal behavior [58], it is difficult to generalize our findings to overall suicidal behavior in ACS patients. However, since more severe types of suicidal behavior are rare in this type of study, previous clinical studies have regarded SI as a phenotype of suicidal behavior in ACS patients [30, 31]. Second, SI was identified using the “suicidal thoughts” item from the MADRS, rather than defined using a separate or formal instrument. However, the predictive feasibility of the suicide-related item for suicide attempts and suicide death has been demonstrated [59], and the approach used in this study has been applied previously [42]. Third, the assessment of diabetes was based on self-reports, which may have underestimated the true prevalence of diabetes at baseline. Fourth, diabetes type and the burden of diabetes-related complications were not evaluated. However, most adults with diabetes in Korea are expected to have type 2 diabetes.

Fifth, the follow-up rate for 1-year re-evaluation was relatively low compared with the baseline evaluation.

Due to the poor prognostic characteristics of the ACS patients who were lost to follow-up, such as older age and a higher Killip class, this might have affected the results. However, this possibility is unlikely because the baseline distributions of diabetes, sBDNF tertile, and *BDNF* Val66Met polymorphism did not differ by the 1-year re-evaluation follow-up status. Finally, recruitment was performed at a single site, which may limit the study’s generalizability; on the other hand, this is also a strength as it ensures consistency in the evaluation and treatment of patients.

This study has several strengths. It is the first prospective investigation to evaluate the interaction effects of diabetes and the BDNF pathway on SI. The BDNF pathway was evaluated using two markers, the sBDNF level and *BDNF* Val66Met polymorphism, which reinforced the validity of our results. All measurements of psychiatric and cardiovascular statuses were conducted using well-validated scales. Moreover, acute SI and other covariates were evaluated at similar time points (within 2 weeks of the ACS episode) in a large number of ACS patients, which reduced the risk of error arising from heterogeneous examination times. The final strength was the consecutive recruitment of participants from all eligible ACS patients seen in the study hospital. This reduced the likelihood of selection bias and increased the generalizability of the outcomes in terms of screening patients at high risk of suicide.

## 5. Conclusion

Baseline diabetes and the high vs. low sBDNF level or *BDNF* Val/Val vs. Met/Met genotype showed multiplicative interactions in their associations with acute SI among patients with ACS. In addition, although the interaction effects were not significant, diabetes was associated with a higher frequency of chronic SI only in patients with a low sBDNF level or with the *BDNF* Met/Met genotype. These results suggest that the combination of diabetes and BDNF-related markers may increase the predictability of acute SI compared with each marker alone. Considering the therapeutic aspects, special attention is needed for ACS patients who have both diabetes and altered BDNF-related markers; however, further studies are needed to evaluate whether additional suicide prevention practices may be beneficial in this subpopulation.

## Declarations

### 6.1 Ethics approval and consent to participant

All patients gave written informed consent to participate in the study and use their data. The study was conducted in accordance with the Helsinki Declaration of 1975, as revised in 2008 and approved by the Ethics Commission of the

Chonnam National University Hospital Institutional Review Board (CNUH I-2008-02-027) as it uses de-identified data.

## 6.2 Consent for publication

Not applicable

## 6.3 Availability of data and materials

Not applicable

## 6.4 Competing interests

Authors declare no other potential conflict of interest relevant to this article

## 6.5 Funding

The study was funded by a grant of National Research Foundation of Korea Grant [NRF- 2020R1A2C2003472, NRF- 2020M3E5D9080733] to Jae-Min Kim. Robert Stewart is part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. Robert Stewart is also a National Institute for Health Research (NIHR) Senior Investigator.

## 6.6 Author's contributions

The study concept, design and interpretation of data were constructed by W.C. and J.-M.K. Statistical analysis was performed by W.C. and J.-M.K. Supervision was conducted by J.-W.K., H.-J.K., H.K.K., H.-C.K., J.-Y.L., S.-W.K., Y.J.H., Y.A., M.H.J., R.S., and J.-M.K. The data acquisition and analysis was conducted by W.C., J.-W.K., H.-J.K., J.-Y.L., S.-W.K., and J.-M.K. Drafting of the manuscript was made by W.C. and J.-M.K. All authors approved to be accountable for all aspects of the work.

## 6.7 Acknowledgements

The authors acknowledge the whole teams of the Depression Translational Research Center in Chonnam National University Hospital.

# Abbreviations

ACS, acute coronary syndrome; SI, suicidal ideation; BDNF, brain-derived neurotrophic factor; sBDNF, serum BDNF; DEPACS, DEpression in ACS; PCR, polymerase chain reaction; LVEF, left ventricular ejection fraction; CK-MB, creatine kinase-MB; MADRS, Montgomery–Åsberg Depression Rating Scale.

# References

1. Naghavi M, Global Burden of Disease Self-Harm C: **Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016.** *BMJ* 2019, **364**:l94.
2. Artero S, Astruc B, Courtet P, Ritchie K: **Life-time history of suicide attempts and coronary artery disease in a community-dwelling elderly population.** *Int J Geriatr Psychiatry* 2006, **21**(2):108-112.
3. Placido A, Sposito AC: **Association between suicide and cardiovascular disease: time series of 27 years.** *Int J Cardiol* 2009, **135**(2):261-262.
4. Larsen KK, Agerbo E, Christensen B, Sondergaard J, Vestergaard M: **Myocardial infarction and risk of suicide: a population-based case-control study.** *Circulation* 2010, **122**(23):2388-2393.

5. Liu CH, Yeh MK, Wang JH, Weng SC, Bai MY, Chang JC: **Acute Coronary Syndrome and Suicide: A Case-Referent Study.** *J Am Heart Assoc* 2016, **5**(12).
6. Kim JM, Stewart R, Lee HJ, Kang HJ, Bae KY, Kim SW, Shin IS, Kim MC, Hong YJ, Ahn Y *et al*: **Impact of Suicidal Ideation on Long-Term Cardiac Outcomes in Patients with Acute Coronary Syndrome: Sex-Specific Differences.** *Psychother Psychosom* 2018, **87**(5):311-312.
7. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM: **Diabetes and mortality following acute coronary syndromes.** *JAMA* 2007, **298**(7):765-775.
8. Lettino M, Andell P, Zeymer U, Widimsky P, Danchin N, Bardaji A, Barrabes JA, Cequier A, Claeys MJ, De Luca L *et al*: **Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes.** *Eur Heart J Cardiovasc Pharmacother* 2017, **3**(4):198-213.
9. Zhou M, Liu J, Hao Y, Liu J, Huo Y, Smith SC, Jr., Ge J, Ma C, Han Y, Fonarow GC *et al*: **Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project.** *Cardiovasc Diabetol* 2018, **17**(1):147.
10. Sarkar S, Balhara YP: **Diabetes mellitus and suicide.** *Indian J Endocrinol Metab* 2014, **18**(4):468-474.
11. Wang B, An X, Shi X, Zhang JA: **MANAGEMENT OF ENDOCRINE DISEASE: Suicide risk in patients with diabetes: a systematic review and meta-analysis.** *Eur J Endocrinol* 2017, **177**(4):R169-R181.
12. Ejiri J, Inoue N, Kobayashi S, Shiraki R, Otsui K, Honjo T, Takahashi M, Ohashi Y, Ichikawa S, Terashima M *et al*: **Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease.** *Circulation* 2005, **112**(14):2114-2120.
13. Manni L, Nikolova V, Vyagova D, Chaldakov GN, Aloe L: **Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes.** *Int J Cardiol* 2005, **102**(1):169-171.
14. Huang EJ, Reichardt LF: **Neurotrophins: roles in neuronal development and function.** *Annu Rev Neurosci* 2001, **24**:677-736.
15. Dwivedi Y: **Brain-derived neurotrophic factor and suicide pathogenesis.** *Ann Med* 2010, **42**(2):87-96.
16. Deveci A, Aydemir O, Taskin O, Taneli F, Esen-Danaci A: **Serum BDNF levels in suicide attempters related to psychosocial stressors: a comparative study with depression.** *Neuropsychobiology* 2007, **56**(2-3):93-97.
17. Grah M, Mihanovic M, Ruljancic N, Restek-Petrovic B, Molnar S, Jelavic S: **Brain-derived neurotrophic factor as a suicide factor in mental disorders.** *Acta Neuropsychiatr* 2014, **26**(6):356-363.
18. Pinheiro RT, Pinheiro KA, da Cunha Coelho FM, de Avila Quevedo L, Gazal M, da Silva RA, Giovenardi M, Lucion AB, de Souza DO, Portela LV *et al*: **Brain-derived neurotrophic factor levels in women with postpartum affective disorder and suicidality.** *Neurochem Res* 2012, **37**(10):2229-2234.
19. Huang TL, Lee CT: **Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients.** *J Psychiatr Res* 2006, **40**(7):664-668.
20. Park YM, Lee BH, Um TH, Kim S: **Serum BDNF levels in relation to illness severity, suicide attempts, and central serotonin activity in patients with major depressive disorder: a pilot study.** *PLoS One* 2014, **9**(3):e91061.
21. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, Lee FS: **Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons.** *J Neurosci* 2004, **24**(18):4401-4411.
22. Kim B, Kim CY, Hong JP, Kim SY, Lee C, Joo YH: **Brain-derived neurotrophic factor Val/Met polymorphism and bipolar disorder. Association of the Met allele with suicidal behavior of bipolar patients.** *Neuropsychobiology* 2008, **58**(2):97-103.
23. Iga J, Ueno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S, Nakataki M, Song H, Hokoishi K, Tanabe H *et al*: **The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with psychotic feature**

- and suicidal behavior in Japanese major depressive patients.** *Am J Med Genet B Neuropsychiatr Genet* 2007, **144B**(8):1003-1006.
24. Sarchiapone M, Carli V, Roy A, Iacoviello L, Cuomo C, Latella MC, di Giannantonio M, Janiri L, de Gaetano M, Janal MN: **Association of polymorphism (Val66Met) of brain-derived neurotrophic factor with suicide attempts in depressed patients.** *Neuropsychobiology* 2008, **57**(3):139-145.
  25. Hong CJ, Huo SJ, Yen FC, Tung CL, Pan GM, Tsai SJ: **Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior.** *Neuropsychobiology* 2003, **48**(4):186-189.
  26. Zarrilli F, Angiolillo A, Castaldo G, Chiariotti L, Keller S, Sacchetti S, Marusic A, Zagar T, Carli V, Roy A *et al*: **Brain derived neurotrophic factor (BDNF) genetic polymorphism (Val66Met) in suicide: a study of 512 cases.** *Am J Med Genet B Neuropsychiatr Genet* 2009, **150B**(4):599-600.
  27. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, Fischer CP, Lindegaard B, Petersen AM, Taudorf S *et al*: **Brain-derived neurotrophic factor (BDNF) and type 2 diabetes.** *Diabetologia* 2007, **50**(2):431-438.
  28. Rozanska O, Uruska A, Zozulinska-Ziolkiewicz D: **Brain-Derived Neurotrophic Factor and Diabetes.** *Int J Mol Sci* 2020, **21**(3).
  29. Beck AT, Kovacs M, Weissman A: **Assessment of suicidal intention: the Scale for Suicide Ideation.** *J Consult Clin Psychol* 1979, **47**(2):343-352.
  30. Nascimento ER, Maia AC, Soares-Filho G, Nardi AE, Cardoso A: **Predictors of suicidal ideation in coronary artery disease.** *Compr Psychiatry* 2015, **57**:16-20.
  31. Kishi Y, Robinson RG, Kosier JT: **Suicidal ideation among patients with acute life-threatening physical illness: patients with stroke, traumatic brain injury, myocardial infarction, and spinal cord injury.** *Psychosomatics* 2001, **42**(5):382-390.
  32. Kim JM, Stewart R, Kang HJ, Bae KY, Kim SW, Shin IS, Hong YJ, Ahn Y, Jeong MH, Kang H *et al*: **Depression following Acute Coronary Syndrome: Time-Specific Interactions between Stressful Life Events, Social Support Deficits, and 5-HTTLPR.** *Psychother Psychosom* 2017, **86**(1):62-64.
  33. Kim JM, Stewart R, Lee YS, Lee HJ, Kim MC, Kim JW, Kang HJ, Bae KY, Kim SW, Shin IS *et al*: **Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial.** *JAMA* 2018, **320**(4):350-358.
  34. Kim JM, Stewart R, Kim JW, Kang HJ, Bae KY, Kim SW, Hong YJ, Ahn Y, Jeong MH, Yoon JS: **Serotonin Transporter Gene Association Between Anxiety and Long-Term Cardiac Outcomes in Acute Coronary Syndromes.** *J Am Coll Cardiol* 2018, **71**(23):2706-2707.
  35. Lee KH, Jeong MH, Kim HM, Ahn Y, Kim JH, Chae SC, Kim YJ, Hur SH, Seong IW, Hong TJ *et al*: **Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol.** *J Am Coll Cardiol* 2011, **58**(16):1664-1671.
  36. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., Chavey WE, 2nd, Fesmire FM, Hochman JS, Levin TN *et al*: **2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.** *J Am Coll Cardiol* 2013, **61**(23):e179-347.
  37. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Jr., Krishnan KR, van Zyl LT, Swenson JR, Finkel MS *et al*: **Sertraline treatment of major depression in patients with acute MI or unstable angina.** *JAMA* 2002, **288**(6):701-709.

38. Kim JM, Kang HJ, Bae KY, Kim SW, Shin IS, Hong YJ, Ahn Y, Jeong MH, Kang H, Yoon JS: **Determinants and escitalopram treatment effects on suicidal ideation in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies.** *Int J Cardiol* 2016, **219**:225-230.
39. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: **An inventory for measuring depression.** *Arch Gen Psychiatry* 1961, **4**:561-571.
40. Killip T, 3rd, Kimball JT: **Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.** *Am J Cardiol* 1967, **20**(4):457-464.
41. Montgomery SA, Asberg M: **A new depression scale designed to be sensitive to change.** *Br J Psychiatry* 1979, **134**:382-389.
42. Murrough JW, Soleimani L, DeWilde KE, Collins KA, Lapidus KA, Iacoviello BM, Lener M, Kautz M, Kim J, Stern JB *et al*: **Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.** *Psychol Med* 2015, **45**(16):3571-3580.
43. Handley TE, Ventura AD, Browne JL, Rich J, Attia JR, Reddy P, Pouwer F, Speight J: **Suicidal ideation reported by adults with Type 1 or Type 2 diabetes: results from Diabetes MILES-Australia.** *Diabet Med* 2016, **33**(11):1582-1589.
44. Petrak F, Baumeister H, Skinner TC, Brown A, Holt RIG: **Depression and diabetes: treatment and health-care delivery.** *Lancet Diabetes Endocrinol* 2015, **3**(6):472-485.
45. The Lancet Diabetes E: **Poor mental health in diabetes: still a neglected comorbidity.** *Lancet Diabetes Endocrinol* 2015, **3**(6):393.
46. Matlock KA, Yayah Jones NH, Corathers SD, Kichler JC: **Clinical and Psychosocial Factors Associated With Suicidal Ideation in Adolescents With Type 1 Diabetes.** *J Adolesc Health* 2017, **61**(4):471-477.
47. Butwicka A, Frisen L, Almqvist C, Zethelius B, Lichtenstein P: **Risks of psychiatric disorders and suicide attempts in children and adolescents with type 1 diabetes: a population-based cohort study.** *Diabetes Care* 2015, **38**(3):453-459.
48. Dahlquist G, Kallen B: **Mortality in childhood-onset type 1 diabetes: a population-based study.** *Diabetes Care* 2005, **28**(10):2384-2387.
49. Batty GD, Kivimaki M, Park IS, Jee SH: **Diabetes and raised blood glucose as risk factors for future suicide: cohort study of 1 234 927 Korean men and women.** *J Epidemiol Community Health* 2012, **66**(7):650-652.
50. Koskinen SV, Reunanen AR, Martelin TP, Valkonen T: **Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus.** *Am J Public Health* 1998, **88**(5):765-770.
51. Yamauchi T, Inagaki M, Yonemoto N, Iwasaki M, Akechi T, Sawada N, Iso H, Noda M, Tsugane S, Group JS: **History of diabetes and risk of suicide and accidental death in Japan: The Japan Public Health Centre-based Prospective Study, 1990-2012.** *Diabetes Metab* 2016, **42**(3):184-191.
52. Davis WA, Starkstein SE, Bruce DG, Davis TM: **Risk of suicide in Australian adults with diabetes: the Fremantle Diabetes Study.** *Intern Med J* 2015, **45**(9):976-980.
53. Ola MS, Nawaz MI, El-Asrar AA, Abouammoh M, Alhomida AS: **Reduced levels of brain derived neurotrophic factor (BDNF) in the serum of diabetic retinopathy patients and in the retina of diabetic rats.** *Cell Mol Neurobiol* 2013, **33**(3):359-367.
54. Sun Q, Tang DD, Yin EG, Wei LL, Chen P, Deng SP, Tu LL: **Diagnostic Significance of Serum Levels of Nerve Growth Factor and Brain Derived Neurotrophic Factor in Diabetic Peripheral Neuropathy.** *Med Sci Monit* 2018, **24**:5943-5950.
55. Autry AE, Monteggia LM: **Brain-derived neurotrophic factor and neuropsychiatric disorders.** *Pharmacol Rev* 2012, **64**(2):238-258.
56. Song H, Fang F, Arnberg FK, Mataix-Cols D, Fernandez de la Cruz L, Almqvist C, Fall K, Lichtenstein P, Thorgeirsson G, Valdimarsdottir UA: **Stress related disorders and risk of cardiovascular disease: population based, sibling**

controlled cohort study. *BMJ* 2019, **365**:l1255.

57. Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW: **Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review.** *J Am Coll Cardiol* 2019, **73**(14):1827-1845.
58. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S *et al*: **The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.** *Am J Psychiatry* 2011, **168**(12):1266-1277.
59. Green KL, Brown GK, Jager-Hyman S, Cha J, Steer RA, Beck AT: **The Predictive Validity of the Beck Depression Inventory Suicide Item.** *J Clin Psychiatry* 2015, **76**(12):1683-1686.

## Tables

**Table 1.**

Comparisons of baseline characteristics according to diabetes presence in patients with acute coronary syndrome

	Non-diabetics (N = 778)	Diabetics (N = 191)	Statistical coefficient <sup>a</sup>	P-value
<b>Socio-demographic characteristics</b>				
Age, mean (SD) years	57.1 (11.2)	62.4 (9.6)	t = -6.526	P < 0.001
Sex, N (%) female	199 (25.6)	70 (36.6)	$\chi^2 = 9.372$	P = 0.002
Education, mean (SD) years	10.0 (4.6)	9.2 (4.7)	t = 2.029	P = 0.043
Marital status, N (%) unmarried	113 (14.5)	28 (14.7)	$\chi^2 = 0.002$	P = 0.962
Living alone, N (%)	70 (9.0)	22 (11.5)	$\chi^2 = 1.134$	P = 0.287
Housing, N (%) rented	129 (16.6)	21 (11.0)	$\chi^2 = 3.658$	P = 0.056
Currently unemployed, N (%)	277 (35.6)	91 (47.6)	$\chi^2 = 9.438$	P = 0.002
<b>Depression characteristics</b>				
Previous depression, N (%)	25 (3.2)	9 (4.7)	$\chi^2 = 1.107$	P = 0.313
Family history of depression, N (%)	18 (2.3)	5 (2.6)	$\chi^2 = 0.061$	P = 0.805
BDI, mean (SD) score	9.6 (8.5)	11.5 (9.0)	t = -2.746	P = 0.006
<b>Cardiac risk factors, N (%)</b>				
Previous ACS	31 (4.0)	8 (4.2)	$\chi^2 = 0.017$	P = 0.898
Family history of ACS	24 (3.1)	7 (3.7)	$\chi^2 = 0.167$	P = 0.683
Hypertension	338 (43.4)	120 (62.8)	$\chi^2 = 23.114$	P < 0.001
Hypercholesterolemia	403 (51.8)	83 (43.5)	$\chi^2 = 4.271$	P = 0.039
Obesity	336 (43.2)	79 (41.4)	$\chi^2 = 0.209$	P = 0.648
Current smoker	319 (41.0)	47 (24.6)	$\chi^2 = 17.538$	P < 0.001
<b>Current cardiac status</b>				
Killip class >1, N (%)	129 (16.6)	39 (23.2)	$\chi^2 = 1.576$	P = 0.209
LVEF, mean (SD)	61.8 (10.8)	58.6 (12.7)	t = 3.237	P = 0.001
Troponin I, mean (SD) mg/dL	9.9 (15.1)	10.0 (14.2)	t = -0.127	P = 0.899
CK-MB, mean (SD) mg/dL	17.6 (37.8)	16.4 (35.1)	t = 0.413	P = 0.680

<sup>a</sup>Independent two-sample t-test or  $\chi^2$  test, as appropriate. BDI, Beck Depression Inventory; ACS, acute coronary syndrome; LVEF, left ventricular ejection fraction; CK-MB, creatine kinase-MB


**Table 2.**

Individual effects of diabetes, *BDNF* Val66Met polymorphism, and tertiles of serum BDNF levels on acute and chronic suicidal ideation in patients with acute coronary syndrome.

Exposure	Group	Acute suicidal ideation				Chronic suicidal ideation			
		N	No. (%) presence	OR (95% CI)		N	No. (%) presence	OR (95% CI)	
				Unadjusted	Adjusted <sup>a</sup>			Unadjusted	Adjusted <sup>a</sup>
Diabetes	Absent	778	148 (19.0)	1.00	1.00	569	63 (11.1)	1.00	1.00
	Present	191	47 (24.6)	1.39 (0.96-2.02)	1.11 (0.69-1.80)	142	24 (16.9)	1.63 (0.98-2.72)	1.50 (0.86-2.62)
sBDNF	High	323	60 (18.6)	1.00	1.00	228	26 (11.4)	1.00	1.00
	Middle	323	59 (18.3)	0.98 (0.66-1.46)	1.05 (0.65-1.70)	249	34 (13.7)	1.21 (0.71-2.08)	1.37 (0.77-2.42)
	Low	323	76 (23.5)	1.35 (0.92-1.97)	1.73 (1.08-2.79)*	234	27 (11.5)	0.99 (0.56-1.75)	1.04 (0.57-1.91)
<i>BDNF</i> genotype	Val/Val	242	36 (14.9)	1.00	1.00	173	18 (10.4)	1.00	1.00
	Val/Met	498	106 (21.3)	1.55 (1.02-2.34)*	1.36 (0.83-2.25)	378	47 (12.4)	1.22 (0.69-2.18)	1.07 (0.58-1.96)
	Met/Met	229	53 (23.1)	1.72 (1.08-2.75)*	1.40 (0.80-2.47)	160	22 (13.8)	1.37 (0.71-2.67)	1.25 (0.63-2.51)

<sup>a</sup>Adjusted for age, sex, education, housing, current unemployment, previous depression, BDI score, hypertension, hypercholesterolemia, current smoking, and LVEF. *BDNF*, brain-derived neurotrophic factor. \*P < 0.05.


# Figures



**Figure 1**

Interaction effects of diabetes and the sBDNF tertile on acute and chronic suicidal ideation in patients with acute coronary syndrome Figure legends: Data are odds ratios (95% confidence interval) adjusted for age, sex, education, housing, current unemployment, previous depression, BDI score, hypertension, hypercholesterolemia, current smoking, and LVEF evaluated at baseline. \*P < 0.05.





**Figure 2**

Interaction effects of diabetes and the BDNF Val66Met polymorphism on acute and chronic suicidal ideation in patients with acute coronary syndrome. Figure legends: Data are odds ratios (95% confidence intervals) adjusted for age, sex, education, housing, current unemployment, previous depression, BDI score, hypertension, hypercholesterolemia, current smoking, and LVEF evaluated at baseline. \*P < 0.05.